Integra LifeSciences (IART) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last year. There are currently 3 sell ratings, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" IART shares.
View IART analyst ratings or view top-rated stocks.

7 equities research analysts have issued 12-month price objectives for Integra LifeSciences' shares. Their IART share price forecasts range from $39.00 to $60.00. On average, they expect the company's stock price to reach $47.29 in the next twelve months. This suggests a possible upside of 25.4% from the stock's current price.
View analysts price targets for IART or view top-rated stocks among Wall Street analysts.

Integra LifeSciences' stock was trading at $56.07 on January 1st, 2023. Since then, IART shares have decreased by 32.7% and is now trading at $37.72.
View the best growth stocks for 2023 here.

Integra LifeSciences saw a decline in short interest in September. As of September 15th, there was short interest totaling 2,420,000 shares, a decline of 5.8% from the August 31st total of 2,570,000 shares. Based on an average trading volume of 636,900 shares, the short-interest ratio is presently 3.8 days. Currently, 3.4% of the company's shares are sold short.
View Integra LifeSciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 25th 2023.
View our IART earnings forecast.

Integra LifeSciences Holdings Co. (NASDAQ:IART) released its quarterly earnings results on Wednesday, July, 26th. The life sciences company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.57 by $0.14. The life sciences company had revenue of $381.30 million for the quarter, compared to the consensus estimate of $388.79 million. Integra LifeSciences had a trailing twelve-month return on equity of 15.60% and a net margin of 8.49%. The company's quarterly revenue was down 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.82 earnings per share.

ETFs with the largest weight of Integra LifeSciences (NASDAQ:IART) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Fidelity Digital Health ETF (FDHT), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Health Care AlphaDEX Fund (FXH), SPDR S&P Health Care Equipment ETF (XHE), WisdomTree U.S. AI Enhanced Value Fund (AIVL) and Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares U.S. Medical Devices ETF (IHI).

Shares of Integra LifeSciences split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were payable to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Integra LifeSciences updated its FY 2023 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $3.10-$3.18 for the period, compared to the consensus earnings per share estimate of $3.12. The company issued revenue guidance of $1.55 billion-$1.56 billion, compared to the consensus revenue estimate of $1.56 billion.

173 employees have rated Integra LifeSciences Chief Executive Officer Peter J. Arduini on Glassdoor.com. Peter J. Arduini has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IART stock can currently be purchased for approximately $37.72.

Integra LifeSciences (NASDAQ:IART) has a market capitalization of $3.07 billion and generates $1.56 billion in revenue each year. The life sciences company earns $180.55 million in net income (profit) each year or $1.57 on an earnings per share basis.

The company employs 3,722 workers across the globe.

Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The official website for the company is www.integralife.com. The life sciences company can be reached via phone at (609) 275-0500, via email at ir@integralife.com, or via fax at 609-750-4277.